Flash Forward is a show about possible (and not so possible) future scenarios. What would the warranty on a sex robot look like? How would diplomacy work if we couldn’t lie? Could there ever be a fecal transplant black market? (Complicated, it wouldn’t, and yes, respectively, in case you’re curious.) Hosted and produced by award winning science journalist Rose Eveleth, each episode combines audio drama and journalism to go deep on potential tomorrows, and uncovers what those futures might re ...
…
continue reading
Вміст надано Oleksandr Yagensky. Весь вміст подкастів, включаючи епізоди, графіку та описи подкастів, завантажується та надається безпосередньо компанією Oleksandr Yagensky або його партнером по платформі подкастів. Якщо ви вважаєте, що хтось використовує ваш захищений авторським правом твір без вашого дозволу, ви можете виконати процедуру, описану тут https://uk.player.fm/legal.
Player FM - додаток Podcast
Переходьте в офлайн за допомогою програми Player FM !
Переходьте в офлайн за допомогою програми Player FM !
Ep#040: Eliminating Cancer Using Invariant Natural Killer T Cells (iNKTs) with Dr. Jennifer Buell
MP3•Головна епізоду
Manage episode 324873457 series 2800366
Вміст надано Oleksandr Yagensky. Весь вміст подкастів, включаючи епізоди, графіку та описи подкастів, завантажується та надається безпосередньо компанією Oleksandr Yagensky або його партнером по платформі подкастів. Якщо ви вважаєте, що хтось використовує ваш захищений авторським правом твір без вашого дозволу, ви можете виконати процедуру, описану тут https://uk.player.fm/legal.
Welcome to the next episode of the Personalized Medicine Podcast. On this podcast we have talked extensively about antibody, vaccine and CAR-T cell based approaches to treat cancer. Today we will be talking about a new approach in oncology that is based on invariant Natural Killer T Cells, or iNKTs.
Our guest today is Dr. Jennifer Buell, the founder, CEO and President of MiNK Therapeutics and the former President and COO of Agenus. Jennifer has over 25 years of experience in the biopharmaceutical space, having held multiple leadership positions at biotech companies. In her tenure at Agenus, she transformed a neoantigen vaccine development startup into a multifaceted company with a strong global footing. She is now leading MiNK therapeutics, the precision oncology company that develops targeted iNKT cells for treatment of various types of cancer and autoimmune diseases.
Together with Jennifer we discussed:
◦ Evolution of immunooncology over the the last two decades
◦ Role of immune system in fighting cancer
◦ Neoantigen vaccines as a tool for personalized cancer treatment
◦ Invariant Natural Killer T Cells (iNKTs) and their role in combating cancer
◦ Advantage of iNKTs over other cancer treatments
◦ Potential of combination therapies in oncology
◦ Challenges in bringing novel cell-based therapies to the market
◦ Advice to budding biotech entrepreneurs
◦ The outlook on the next decade of cancer treatment
Get in touch with Jennifer:
LinkedIn: Jennifer S. Buell
Twitter: @jbuell01
Web: https://minktherapeutics.com/
…
continue reading
Our guest today is Dr. Jennifer Buell, the founder, CEO and President of MiNK Therapeutics and the former President and COO of Agenus. Jennifer has over 25 years of experience in the biopharmaceutical space, having held multiple leadership positions at biotech companies. In her tenure at Agenus, she transformed a neoantigen vaccine development startup into a multifaceted company with a strong global footing. She is now leading MiNK therapeutics, the precision oncology company that develops targeted iNKT cells for treatment of various types of cancer and autoimmune diseases.
Together with Jennifer we discussed:
◦ Evolution of immunooncology over the the last two decades
◦ Role of immune system in fighting cancer
◦ Neoantigen vaccines as a tool for personalized cancer treatment
◦ Invariant Natural Killer T Cells (iNKTs) and their role in combating cancer
◦ Advantage of iNKTs over other cancer treatments
◦ Potential of combination therapies in oncology
◦ Challenges in bringing novel cell-based therapies to the market
◦ Advice to budding biotech entrepreneurs
◦ The outlook on the next decade of cancer treatment
Get in touch with Jennifer:
LinkedIn: Jennifer S. Buell
Twitter: @jbuell01
Web: https://minktherapeutics.com/
48 епізодів
MP3•Головна епізоду
Manage episode 324873457 series 2800366
Вміст надано Oleksandr Yagensky. Весь вміст подкастів, включаючи епізоди, графіку та описи подкастів, завантажується та надається безпосередньо компанією Oleksandr Yagensky або його партнером по платформі подкастів. Якщо ви вважаєте, що хтось використовує ваш захищений авторським правом твір без вашого дозволу, ви можете виконати процедуру, описану тут https://uk.player.fm/legal.
Welcome to the next episode of the Personalized Medicine Podcast. On this podcast we have talked extensively about antibody, vaccine and CAR-T cell based approaches to treat cancer. Today we will be talking about a new approach in oncology that is based on invariant Natural Killer T Cells, or iNKTs.
Our guest today is Dr. Jennifer Buell, the founder, CEO and President of MiNK Therapeutics and the former President and COO of Agenus. Jennifer has over 25 years of experience in the biopharmaceutical space, having held multiple leadership positions at biotech companies. In her tenure at Agenus, she transformed a neoantigen vaccine development startup into a multifaceted company with a strong global footing. She is now leading MiNK therapeutics, the precision oncology company that develops targeted iNKT cells for treatment of various types of cancer and autoimmune diseases.
Together with Jennifer we discussed:
◦ Evolution of immunooncology over the the last two decades
◦ Role of immune system in fighting cancer
◦ Neoantigen vaccines as a tool for personalized cancer treatment
◦ Invariant Natural Killer T Cells (iNKTs) and their role in combating cancer
◦ Advantage of iNKTs over other cancer treatments
◦ Potential of combination therapies in oncology
◦ Challenges in bringing novel cell-based therapies to the market
◦ Advice to budding biotech entrepreneurs
◦ The outlook on the next decade of cancer treatment
Get in touch with Jennifer:
LinkedIn: Jennifer S. Buell
Twitter: @jbuell01
Web: https://minktherapeutics.com/
…
continue reading
Our guest today is Dr. Jennifer Buell, the founder, CEO and President of MiNK Therapeutics and the former President and COO of Agenus. Jennifer has over 25 years of experience in the biopharmaceutical space, having held multiple leadership positions at biotech companies. In her tenure at Agenus, she transformed a neoantigen vaccine development startup into a multifaceted company with a strong global footing. She is now leading MiNK therapeutics, the precision oncology company that develops targeted iNKT cells for treatment of various types of cancer and autoimmune diseases.
Together with Jennifer we discussed:
◦ Evolution of immunooncology over the the last two decades
◦ Role of immune system in fighting cancer
◦ Neoantigen vaccines as a tool for personalized cancer treatment
◦ Invariant Natural Killer T Cells (iNKTs) and their role in combating cancer
◦ Advantage of iNKTs over other cancer treatments
◦ Potential of combination therapies in oncology
◦ Challenges in bringing novel cell-based therapies to the market
◦ Advice to budding biotech entrepreneurs
◦ The outlook on the next decade of cancer treatment
Get in touch with Jennifer:
LinkedIn: Jennifer S. Buell
Twitter: @jbuell01
Web: https://minktherapeutics.com/
48 епізодів
Semua episode
×Ласкаво просимо до Player FM!
Player FM сканує Інтернет для отримання високоякісних подкастів, щоб ви могли насолоджуватися ними зараз. Це найкращий додаток для подкастів, який працює на Android, iPhone і веб-сторінці. Реєстрація для синхронізації підписок між пристроями.